Given the rapid and robust nature of the K18-hACE2 mouse model, antiviral activity of mAb treatment is often demonstrated in this model by administering the mAb prior to infection [48,49,50,52], although some mAb cocktails have shown significant anti-viral activity if given 24 h after infection [50]. Here, KRT18 is linked to infection.